Mitotane and Erlotinib: Interaction Details
- Mitotane
- Lysodren
- Erlotinib
- Tarceva
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Mitotane and Erlotinib interaction:
What Happens When You Take Mitotane With Erlotinib
What can happen when they are taken together (rated Major)
Decreased erlotinib exposure and potential loss of
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
Whenever feasible, erlotinib (a ) should not be given together with a CYP3A4 , because the combination can lower erlotinib exposure and reduce its efficacy. In a study of erlotinib given with rifabutin, a CYP3A4 inducer, the erlotinib fell by 58% to 80%. When the combination cannot be avoided, the recommendation is to raise the erlotinib dose as tolerated, in 50 mg steps every 2 weeks, up to a maximum of 450 mg.1
The Mitotane and Erlotinib Interaction, Explained
Mitotane can make erlotinib work less well. Mitotane speeds up an enzyme in the liver () that breaks down erlotinib, so less of the cancer medicine stays in your body. That could mean it doesn't control your cancer as well as it should. This is based on how the drugs are expected to behave rather than on a direct study of these two together.
Please keep taking both medicines exactly as prescribed. Your care team may be able to adjust your erlotinib dose and watch you more closely, so be sure they know you take mitotane.
Mechanism: Mitotane is a ; erlotinib is a CYP3A4 . increases erlotinib and lowers exposure (), with risk of reduced . Neither drug's activity depends on activation here.
- Magnitude: No mitotane-specific data. With rifabutin (CYP3A4 inducer), erlotinib AUC fell 58% to 80%.
- Evidence: Theoretical for this pair. Onset unspecified. Severity on file: major.
- Management: Avoid combination if possible. If unavoidable, increase erlotinib in 50 mg increments at 2 week intervals as tolerated, to a maximum of 450 mg. Monitor for tolerability, adverse effects, and clinical response.
See the 1 reference behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Mitotane and Erlotinib Interact
The likely mechanism
of -mediated erlotinib
How to Manage the Mitotane and Erlotinib Interaction
Your care team will usually try to avoid this combination if they can. If you need both, they may raise your erlotinib dose in small steps (50 mg at a time, every 2 weeks, up to a set maximum) as long as you tolerate it. Your dose may need to be individualized, and your team may monitor you more closely.
- Keep taking both medicines as prescribed, and do not change doses yourself.
- Tell your pharmacist and doctor about all medicines you take, including any new ones.
- Report new or worsening side effects or symptoms promptly.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Mitotane or Erlotinib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there another option that avoids this interaction?
Literature Reports
1 report from the published literature. Each one is headed by the title of the published study it comes from.
What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.
-
Report 1 · Study title
Prescribing information: TARCEVA oral tablets, erlotinib oral tablets
When erlotinib was given together with rifampin, a , the erlotinib was reduced by 58% to 80%.1
Mitotane and Erlotinib: Common Questions
How serious is the Mitotane and Erlotinib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How is the Mitotane and Erlotinib interaction managed?
Your care team will usually try to avoid this combination if they can. If you need both, they may raise your erlotinib dose in small steps (50 mg at a time, every 2 weeks, up to a set maximum) as long as you tolerate it. Your dose may need to be individualized, and your team may monitor you more closely. Keep taking both medicines as prescribed, and do not change doses yourself. Tell your pharmaci… Management is individual — always follow your own care team's guidance.
Does taking Mitotane and Erlotinib at different times of day help?
No. Taking them at different times of day does not prevent this one. Mitotane speeds up , an enzyme that breaks down erlotinib, so erlotinib can be cleared faster. That change lasts while mitotane is being taken and can continue for a while after the last dose.
Your pharmacist or prescriber can tell you how they will manage it.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
Ask About the Mitotane and Erlotinib Interaction
Ask in your own words about taking Mitotane and Erlotinib together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (1)
- Product Information: TARCEVA(R) oral tablets, erlotinib oral tablets. Genentech USA Inc (per FDA), South San Francisco, CA, 2016. DailyMed
Other Serious Interactions of Mitotane and Erlotinib
Also serious with Mitotane
- DoravirineContraindicated
- FostemsavirContraindicated
- Lenacapavir OralContraindicated
- LurasidoneContraindicated
Also serious with Erlotinib
These Medications Also Interact With Supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
With Mitotane
- Activated CharcoalMajor
- Slippery ElmModerate
- GlucomannanModerate
- TragacanthModerate
- Coffee CharcoalModerate
- European MandrakeModerate
- Guar GumModerate
- Gum ArabicModerate
- + 9 more
With Erlotinib
- Activated CharcoalMajor
- BilberryModerate
- Slippery ElmModerate
- GlucomannanModerate
- TragacanthModerate
- Coffee CharcoalModerate
- European MandrakeModerate
- Guar GumModerate
- + 10 more
Check everything you take with our drug–supplement interaction checker.
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, as soon as they can.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring. This interaction.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data.
- ProbableGood supporting evidence, though not definitively proven.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized. This interaction.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.